Notably, sodium‒glucose cotransporter-2 (SGLT2) inhibitors have shown efficacy in slowing CKD progression and offer additional cardiovascular benefits, weight loss, and a reduction in blood pressure in individuals with type 2 diabetes mellitus (DM), leading to increased utilization of these agents for these purposes 3-5. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.